Accustem Sciences Inc.

0.1600

-0.0650-28.89%

Volume:41.52K

Turnover:7.45K

Market Cap:2.57M

PE:-1.52

High:0.2300

Open:0.2300

Low:0.1600

Close:0.2250

52wk High:2.25

52wk Low:0.1515

Shares:16.07M

Float Shares:7.89M

Volume Ratio:8.42

T/O Rate:0.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1055

ROE:-1794.16%

ROA:-64.16%

PB:-0.62

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/ACUT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACUT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUT\",,,,,undefined,":{"symbol":"ACUT","market":"US","secType":"STK","nameCN":"Accustem Sciences Inc.","latestPrice":0.16,"timestamp":1787342400000,"preClose":0.225,"halted":0,"volume":41517,"delay":15,"changeRate":-0.2888888888888889,"floatShares":7885954,"shares":16072267,"eps":-0.105519,"marketStatus":"Pre-Mkt","change":-0.065,"latestTime":"08-21 16:00:00 EDT Delay","open":0.23,"high":0.23,"low":0.16,"amount":7445.042399999998,"amplitude":0.311111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.105519,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"OTCQB","adjPreClose":0.16,"volumeRatio":8.41856611920782},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUT\",,,,,undefined,":{"symbol":"ACUT","floatShares":7885954,"roa":"-64.16%","roe":"-1794.16%","lyrEps":0,"volumeRatio":8.41856611920782,"shares":16072267,"dividePrice":0,"high":0.23,"amplitude":0.311111,"preClose":0.225,"low":0.16,"week52Low":0.1515,"pbRate":"-0.62","psRate":"26.13","week52High":2.25,"institutionHeld":0,"latestPrice":0.16,"eps":-0.105519,"divideRate":0,"volume":41517,"delay":15,"ttmEps":-0.105519,"open":0.23,"prevYearClose":0.81351,"prevWeekClose":0.16,"prevMonthClose":0.2095,"prevQuarterClose":0.2854,"fiveDayClose":0.156,"twentyDayClose":0.19,"sixtyDayClose":0.2575},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACUT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-16","symbol":"ACUT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1726459200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-20","symbol":"ACUT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1716177600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACUT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACUT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACUT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659129845","title":"AccuStem Q2 FY26 Net Loss Narrows 37% to $252,573","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129845","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129845?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:13","pubTimestamp":1786738381,"startTime":"0","endTime":"0","summary":"AccuStem Q2 FY26 net loss narrows 37% to $252,573AccuStem posted a net loss of USD 252,573 for the quarter ended June 30, 2026, narrowing 37% year over year.Other income turned positive to USD 98,400,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL8G8T6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635371120","title":"AccuStem net loss widens 10% to $485,883 in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635371120","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635371120?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:10","pubTimestamp":1778875824,"startTime":"0","endTime":"0","summary":"Accustem Sciences posted a net loss of $485,883 for three months ended March 31, 2026, widening 10% from a year earlier; operating loss also widened 10% to $485,883.Research and development expenses more than quadrupled to $119,525, up 322%, while general and administrative costs fell 11% to $366,358.Cash and cash equivalents ended period at $12,207, down from $13,929 at start of quarter; cash used in operating activities rose to $374,176 from $290,182.Company reiterated plan to launch MSC lung test for clinical use in early 2027, with transfer of MSC to partner lab EmeritusDx under way ahead of CLIA certification and reimbursement efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7XzfQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627642436","title":"Accustem FY25 net loss widens 16.68% to $1,756,096","url":"https://stock-news.laohu8.com/highlight/detail?id=2627642436","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627642436?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:33","pubTimestamp":1776198821,"startTime":"0","endTime":"0","summary":"Accustem Sciences posted a net loss of $1,756,096, widening 16.68%.Operating loss widened to $1,756,096 as research and development expense more than doubled to $281,014.General and administrative costs rose 8% to $1,475,082 on higher public relations, travel and professional fees.Accustem completed a commercial lab agreement with EmeritusDx and expects existing cash of $13,929 to fall short of funding needs beyond January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL7d4TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514557","title":"Accustem Sciences delays filing annual report, expects 10-K within 15 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514557","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514557?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:57","pubTimestamp":1775005023,"startTime":"0","endTime":"0","summary":"Accustem Sciences disclosed a delay in filing its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Management expects to file within 15 calendar days following original due date.Filing was delayed due to time constraints tied to compiling, disseminating, and reviewing required information.Notice indicated no anticipated significant change in results of operations versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1krTJh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ACUT\",params:#limit:6,delay:false,,,undefined,":[]}}